The effects of acute and repeated oroxylin A treatments on Aβ25-35-induced memory impairment in mice

Neuropharmacology

Volumn 55, Issue 5, 2008, Pages 639-647

  Kim, Dong Hyun ^a   Kim, Sunho ^a   Jeon, Su Jin ^b   Son, Kun Ho ^b   Lee, Seungjoo ^a   Yoon, Byung Hoon ^a   Cheong, Jae Hoon ^c   Ko, Kwang Ho ^d   Ryu, Jong Hoon ^a  

^a Kyung Hee University   (South Korea)

^b Andong National University   (South Korea)

^c Sahmyook University   (South Korea)

^d Seoul National University   (South Korea)

Author keywords

Amyloid protein; Choline acetyltransferase; Glial fibrillary acidic protein; Inducible nitric oxide synthase; Microglia; Oroxylin A; Passive avoidance task; Y maze task

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; AMYLOID BETA PROTEIN[25-35]; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; CELL MARKER; CHOLINE ACETYLTRANSFERASE; DIAZEPAM; GLIAL FIBRILLARY ACIDIC PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; OROXYLIN A; OX 42; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLINERGIC NERVE CELL; CONTROLLED STUDY; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; LIPID PEROXIDATION; MACROGLIA; MALE; MAZE TEST; MEDICINAL PLANT; MEMORY DISORDER; MICROGLIA; MOUSE; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; PASSIVE AVOIDANCE; PRIORITY JOURNAL; REPEATED DRUG DOSE; SCUTELLARIA BAICALENSIS; SINGLE DRUG DOSE; WESTERN BLOTTING;

AMYLOID BETA-PROTEIN; ANALYSIS OF VARIANCE; ANIMALS; ANTIGENS, CD11B; BEHAVIOR, ANIMAL; DIAZEPAM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; EXPLORATORY BEHAVIOR; FLAVONOIDS; FREE RADICAL SCAVENGERS; GABA MODULATORS; GLIAL FIBRILLARY ACIDIC PROTEIN; HIPPOCAMPUS; LIPID PEROXIDATION; MALE; MAZE LEARNING; MEMORY DISORDERS; MICE; MICE, INBRED ICR; PEPTIDE FRAGMENTS; REACTION TIME;

EID: 51049123404     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2008.05.019     Document Type: Article

References (47)

1. Ayasolla K., Khan M., Singh A.K., and Singh I. Inflammatory mediator and β-amyloid (25-35)-induced ceramide generation and iNOS expression are inhibited by vitamin E. Free Radical Biology and Medicine 37 (2004) 325-338
2. Behl C. Alzheimer's disease and oxidative stress: implications for novel therapeutic approaches. Progress in Neurobiology 57 (1999) 301-323
3. Boje K.M., and Arora P.K. Microglial-produced nitric oxide and reactive nitrogen oxides mediate neuronal cell death. Brain Research 587 (1992) 250-256
4. Braak H., and Braak E. Diagnostic criteria for neuropathologic assessment of Alzheimer's disease. Neurobiology of Aging 18 (1997) 85-88
5. Chao C.C., Hu S., Molitor T.W., Shaskan E.G., and Peterson P.K. Activated microglia mediate neuronal cell injury via a nitric oxide mechanism. Journal of Immunology 149 (1992) 2736-2741
6. Chen S.Y., Wright J.W., and Barnes C.D. The neurochemical and behavioral effects of β-amyloid peptide(25-35). Brain Research 720 (1996) 54-60
7. Chen Y., Yang L., and Lee T.J. Oroxylin A inhibition of lipopolysaccharide-induced iNOS and COX-2 gene expression via suppression of nuclear factor-κB activation. Biochemical Pharmacology 59 (2000) 1445-1457
8. Dutar P., Bassant M.H., Senut M.C., and Lamour Y. The septohippocampal pathway: structure and function of a central cholinergic system. Physiological Reviews 75 (1995) 393-427
9. Fan R., Xu F., Previti M.L., Davis J., Grande A.M., Robinson J.K., and Van Nostrand W.E. Minocycline reduces microglial activation and improves behavioral deficits in a transgenic model of cerebral microvascular amyloid. The Journal of Neuroscience 27 (2007) 3057-3063
10. Flood J.F., Morley J.E., and Roberts E. Amnestic effects in mice of four synthetic peptides homologous to amyloid β protein from patients with Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America 88 (1991) 3363-3366
11. Floyd R.A., and Hensley K. Oxidative stress in brain aging. Implications for therapeutics of neurodegenerative diseases. Neurobiology of Aging 23 (2002) 795-807
12. Fu H., Li W., Lao Y., Luo J., Lee N.T., Kan K.K., Tsang H.W., Tsim K.W., Pang Y., Li Z., Chang D.C., Li M., and Han Y. Bis(7)-tacrine attenuates β amyloid-induced neuronal apoptosis by regulating L-type calcium channels. Journal of Neurochemistry 98 (2006) 1400-1410
13. Giovannelli L., Casamenti F., Scali C., Bartolini L., and Pepeu G. Differential effects of amyloid peptides β-(1-40) and β-(25-35) injections into the rat nucleus basalis. Neuroscience 66 (1995) 781-792
14. Griffin W.S., Sheng J.G., Royston M.C., Gentleman S.M., McKenzie J.E., Graham D.I., Roberts G.W., and Mrak R.E. Glial-neuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression. Brain Pathology 8 (1998) 65-72
15. Hommes F.A. Loss of neurotransmitter receptors by hyperphenylalaninemia in the HPH-5 mouse brain. Acta Paediatrica Supplementum 407 (1994) 120-121
16. Huang W.H., Lee A.R., and Yang C.H. Antioxidative and anti-inflammatory activities of polyhydroxyflavonoids of Scutellaria baicalensis GEORGI. Bioscience, Biotechnology, and Biochemistry 70 (2006) 2371-2380
17. Imperato A., Dazzi L., Obinu M.C., Gessa G.L., and Biggio G. Inhibition of hippocampal acetylcholine release by benzodiazepines: antagonism by flumazenil. European Journal of Pharmacology 238 (1993) 35-37
18. Jiwajinda S., Santisopasri V., Murakami A., Kim O.K., Kim H.W., and Ohigashi H. Suppressive effects of edible Thai plants on superoxide and nitric oxide generation. Asian Pacific Journal of Cancer Preview 3 (2002) 215-223
19. Kim M.S., Sung M.J., Seo S.B., Yoo S.J., Lim W.K., and Kim H.M. Water-soluble chitosan inhibits the production of pro-inflammatory cytokine in human astrocytoma cells activated by amyloid β peptide and interleukin-1β. Neuroscience Letters 321 (2002) 105-109
20. Kim D.H., Jeon S.J., Son K.H., Jung J.W., Lee S., Yoon B.H., Choi J.W., Cheong J.H., Ko K.H., and Ryu J.H. Effect of the flavonoid, oroxylin A, on transient cerebral hypoperfusion-induced memory impairment in mice. Pharmacology Biochemistry and Behavior 85 (2006) 658-668
21. Kim D.H., Jeon S.J., Son K.H., Jung J.W., Lee S., Yoon B.H., Lee J.J., Cho Y.W., Cheong J.H., Ko K.H., and Ryu J.H. The ameliorating effect of oroxylin A on scopolamine-induced memory impairment in mice. Neurobiology of Learning and Memory 87 (2007) 536-546
22. Klementiev B., Novikova T., Novitskaya V., Walmod P.S., Dmytriyeva O., Pakkenberg B., Berezin V., and Bock E. A neural cell adhesion molecule-derived peptide reduces neuropathological signs and cognitive impairment induced by Aβ 25-35. Neuroscience 145 (2007) 209-224
23. Koo E.H., Lansbury Jr. P.T., and Kelly J.W. Amyloid diseases: abnormal protein aggregation in neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America 96 (1999) 9989-9990
24. Laursen S.E., and Belknap J.K. Intracerebroventricular injections in mice. Some methodological refinements. Journal of Pharmacological Methods 16 (1986) 355-357
25. Leutner S., Eckert A., and Müller W.E. ROS generation, lipid peroxidation and antioxidant enzyme activities in the aging brain. Journal of Neural Transmission 108 (2001) 955-967
26. Mattson M.P., Cheng B., Davis D., Bryant K., Lieberburg I., and Rydel R.E. β-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. The Journal of Neuroscience 12 (1992) 376-389
27. Maurice T., Lockhart B.P., and Privat A. Amnesia induced in mice by centrally administered β-amyloid peptides involves cholinergic dysfunction. Brain Research 706 (1996) 181-193
28. McGeer E.G., and McGeer P.L. Brain inflammation in Alzheimer disease and the therapeutic implications. Current Pharmaceutical Design 5 (1999) 821-836
29. Miwa C., and Ueki A. Effects of entorhinal cortex lesion on learning behavior and on hippocampus in the rat. Psychiatry and Clinical Neurosciences 50 (1996) 223-230
30. Moor E., DeBoer P., and Westerink B.H. GABA receptors and benzodiazepine binding sites modulate hippocampal acetylcholine release in vivo. European Journal of Pharmacology 359 (1998) 119-126
31. Oh J.K., Hyun S.Y., Oh H.R., Jung J.W., Park C., Lee S.Y., Park J.H., Kim S.Y., Kim K.H., Kim Y.K., and Ryu J.H. Effects of Anemarrhena asphodeloides on focal ischemic brain injury induced by middle cerebral artery occlusion in rats. Biological and Pharmaceutical Bulletin 30 (2007) 38-43
32. Onozuka M., Watanabe K., Nagasaki S., Jiang Y., Ozono S., Nishiyama K., Kawase T., Karasawa N., and Nagatsu I. Impairment of spatial memory and changes in astroglial responsiveness following loss of molar teeth in aged SAMP8 mice. Behavioural Brain Research 108 (2000) 145-155
33. Pappolla M.A., Chyan Y.J., Omar R.A., Hsiao K., Perry G., Smith M.A., and Bozner P. Evidence of oxidative stress and in vivo neurotoxicity of β-amyloid in a transgenic mouse model of Alzheimer's disease: a chronic oxidative paradigm for testing antioxidant therapies in vivo. The American Journal of Pathology 152 (1998) 871-877
34. Pappolla M.A., Chyan Y.J., Poeggeler B., Frangione B., Wilson G., Ghiso J., and Reiter R.J. An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: implications for Alzheimer's disease. Journal of Neural Transmission 107 (2000) 203-231
35. Pedersen W.A., and Blusztajn J.K. Characterization of the acetylcholine-reducing effect of the amyloid-β peptide in mouse SN56 cells. Neuroscience Letters 239 (1997) 77-80
36. Pike C.J., Walencewicz-Wasserman A.J., Kosmoski J., Cribbs D.H., Glabe C.G., and Cotman C.W. Structure-activity analyses of β-amyloid peptides: contributions of the β25-35 region to aggregation and neurotoxicity. Journal of Neurochemistry 64 (1995) 253-265
37. Rogers J.L., and Kesner R.P. Cholinergic modulation of the hippocampus during encoding and retrieval of tone/shock-induced fear conditioning. Learning and Memory 11 (2004) 102-107
38. Schubert P., Ogata T., Miyazaki H., Marchini C., Ferroni S., and Rudolphi K. Pathological immuno-reactions of glial cells in Alzheimer's disease and possible sites of interference. Journal of Neural Transmission Supplementum 54 (1998) 167-174
39. Schubert P., Ogata T., Marchini C., and Ferroni S. Glia-related pathomechanisms in Alzheimer's disease: a therapeutic target?. Mechanisms of Ageing and Development 123 (2001) 47-57
40. Stepanichev M.Yu., Lazareva N.A., Onufriev M.V., Mitrokhina O.S., Moiseeva Yu.V., and Gulyaeva N.V. Effects of doses of fragment (25-35) of β-amyloid peptide on behavior in rats. Neuroscience and Behavioral Physiology 28 (1998) 564-566
41. Terry R.D. The fine structure of neurofibrillary tangles in alzheimer's disease. Journal of Neuropathology and Experimental Neurology 22 (1963) 629-642
42. Tomimori T., Miyaichi Y., and Kizu H. On the flavonoid constituents from the roots of Scutellaria baicalensis Georgi. Yakugaku Zasshi 102 (1982) 388-391
43. A receptors modulate acetylcholine release in feline basal forebrain. The European Journal of Neuroscience 17 (2003) 249-259
44. Whitehouse P.J., Struble R.G., Hedreen J.C., Clark A.W., and Price D.L. Alzheimer's disease and related dementias: selective involvement of specific neuronal systems. CRC Critical Reviews in Clinical Neurobiology 1 (1985) 319-339
45. Wilcock G.K., Esiri M.M., Bowen D.M., and Smith C.C. Alzheimer's disease. Correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities. Journal of the Neurological Sciences 57 (1982) 407-417
46. Yamaguchi Y., and Kawashima S. Effects of amyloid-β-(25-35) on passive avoidance, radial-arm maze learning and choline acetyltransferase activity in the rat. European Journal of Pharmacology 412 (2001) 265-272
47. Yatin S.M., Varadarajan S., and Butterfield D.A. Vitamin E prevents Alzheimer's amyloid β-peptide (1-42)-induced neuronal protein oxidation and reactive oxygen species production. Journal of Alzheimer's Disease 2 (2000) 123-131